Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers

Nature Nanotechnology

Volumn 11, Issue 4, 2016, Pages 372-377

  Schöttler, Susanne ^a,b   Becker, Greta ^a   Winzen, Svenja ^a   Steinbach, Tobias ^a   Mohr, Kristin ^a   Landfester, Katharina ^a   Mailänder, Volker ^a,b   Wurm, Frederik R ^a  

^a MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORPTION; DRUG DELIVERY; ETHYLENE; ETHYLENE GLYCOL; GLYCOPROTEINS; MASS SPECTROMETRY; POLYETHYLENE GLYCOLS; POLYOLS;

APOLIPOPROTEINS; CELLULAR UPTAKE; COVALENT ATTACHMENT; DRUG DELIVERY VEHICLES; MASS SPECTROMETRIC ANALYSIS; POLYMER-MODIFIED; PROTEIN ADSORPTION; PROTEIN CORONAS;

PROTEINS;

APOLIPOPROTEIN; CLUSTERIN; MACROGOL; NANOCARRIER; PLASMA PROTEIN; POLY(ETHYL ETHYLENE PHOSPHATE); POLYSTYRENE; PROTEIN CORONA; UNCLASSIFIED DRUG; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE; POLYESTER;

ADSORPTION; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CELL MEMBRANE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; LASER MICROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; CHEMISTRY; METABOLISM;

ADSORPTION; BLOOD PROTEINS; CLUSTERIN; DRUG CARRIERS; HUMANS; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 84958078423     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2015.330     Document Type: Article

References (50)

1. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nature Nanotech. 8, 772-781 (2013).
2. Cedervall, T. et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050-2055 (2007).
3. Monopoli, M. P., Aberg, C, Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nature Nanotech. 7, 779-786 (2012).
4. Aggarwal, P. et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61, 428-437 (2009).
5. Sacchetti, C. et al. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano 7, 1974-1989 (2013).
6. Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458 (2005).
7. Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442-1448 (2011).
8. Baier, G. et al. Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. Biomacromolecules 13, 2704-2715 (2012).
9. Landfester, K. & Mailander, V. Nanocapsules with specific targeting and release properties using miniemulsion polymerization. Expert Opin. Drug Deliv. 10, 593-609 (2013).
10. Worz, A. et al. Protein-resistant polymer surfaces. J. Mater. Chem. 22, 19547-19561 (2012).
11. Otsuka, H., Nagasaki, Y. & Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 64, 246-255 (2012).
12. Pino, P. d. et al. Protein corona formation around nanoparticles-from the past to the future. Mater. Horiz. 1, 301-313 (2014).
13. Pelegri-O'Day, E. M., Lin, E. W. & Maynard, H. D. Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J. Am. Chem. Soc. 136, 14323-14332 (2014).
14. Gref, R. et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18, 301-313 (2000).
15. Kim, H. R. et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and protein lab-on-chip system. Electrophoresis 28, 2252-2261 (2007).
16. Ishida, T. et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control Rel. 112, 15-25 (2006).
17. Ishida, T. & Kiwada, H. Anti-polyethyleneglycol antibody response to PEGylated substances. Biol. Pharm. Bull. 36, 889-891 (2013).
18. Shah, S., Prematta, T., Adkinson, N. F. & Ishmael, F. T. Hypersensitivity to polyethylene glycols. J. Clin. Pharmacol. 53, 352-355 (2013).
19. Bertrand, N. & Leroux, J. C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Rel. 161, 152-163 (2012).
20. Hamad, I., Hunter, A. C, Szebeni, J. & Moghimi, S. M. Polyethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225-232 (2008).
21. Amoozgar, Z. & Yeo, Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4, 219-233 (2012).
22. Steinbach, T., Ritz, S. & Wurm, F. R. Water-soluble poly(phosphonate)s via living ring-opening polymerization. ACS Macro Lett. 3, 244-248 (2014).
23. Marsico, F. et al. Hyperbranched unsaturated polyphosphates as a protective matrix for long-term photon upconversion in air. J. Am. Chem. Soc. 136, 11057-11064 (2014).
24. Troev, K. D. Polyphosphoesters: Chemistry and Application (Elsevier, 2012).
25. Steinbach, T. & Wurm, F. R. Poly(phosphoester)s: a new platform for degradable polymers. Angew. Chem. Int. Ed. 54, 6098-6108 (2015).
26. Zhang, S. Y. et al. Polyethylene oxide)-block-polyphosphester-based paclitaxel conjugates as a platform for ultra-high paclitaxel-loaded multifunctional nanoparticles. Chem. Sci. 4, 2122-2126 (2013).
27. Wang, Y. C. et al. Recent progress in polyphosphoesters: from controlled synthesis to biomedical applications. Macromol. Biosci. 9, 1154-1164 (2009).
28. Holzapfel, V. et al. Preparation of fluorescent carboxyl and amino functionalized polystyrene particles by miniemulsion polymerization as markers for cells. Macromol. Chem. Phys. 206, 2440-2449 (2005).
29. Kuga, S. Pore-size distribution analysis of gel substances by size exclusion chromatography. J. Chromatogr. A 206, 449-461 (1981).
30. Kang, B. et al. Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials 49, 125-134 (2015).
31. Tenzer, S. et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5, 7155-7167 (2011).
32. Ritz, S. et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 16, 1311-1321 (2015).
33. Walkey, C. D. & Chan, W. C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780-2799 (2012).
34. Goppert, T. M. & Muller, R. H. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int. J. Pharm. 302, 172-186 (2005).
35. Blunk, T. et al. Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14, 1382-1387 (1993).
36. Gessner, A. et al. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int. J. Pharm. 196, 245-249 (2000).
37. Vanhooren, V. et al. Protein modification and maintenance systems as biomarkers of ageing. Mech. Ageing Dev. 151, 71-84 (2015).
38. Koltai, T. Clusterin: a key player in cancer chemoresistance and its inhibition. Oncol. Targets Ther. 7, 447-456 (2014).
39. Blaschuk, O., Burdzy, K. & Fritz, I. B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 258, 7714-7720 (1983).
40. Nilselid, A. M. et al. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 48, 718-728 (2006).
41. Silajdzic, E., Minthon, L., Bjorkqvist, M. & Hansson, O. No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS ONE 7, e50237 (2012).
42. Poon, S. et al. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39, 15953-15960 (2000).
43. Jenne, D. E. & Tschopp, J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17, 154-159 (1992).
44. Thiele, L. et al. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 24, 1409-1418 (2003).
45. Winzen, S. et al. Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. Nanoscale 7, 2992-3001 (2015).
46. Rodriguez, P. L. et al. Minimal 'self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013).
47. Walkey, C. D. et al. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134, 2139-2147 (2012).
48. Barran-Berdon, A. L. et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29, 6485-6494 (2013).
49. Zensi, A. et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Rel. 137, 78-86 (2009).
50. Kreuter, J. et al. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Control. Rel. 118, 54-58 (2007).